Paper41803255
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.
Chen GM and 36 others. Nat Biomed Eng, 2026. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. Papers, record 41803255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41803255
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptors, Chimeric Antigen | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Biomarkers, Tumor | Major topic |
| Hematologic Neoplasms | Major topic |
| Humans | |
| T-Lymphocytes | |
| Flow Cytometry |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 CA214278 | NCI NIH HHS | United States | P01CA214278 | PubMed | NIH RePORTER |
| P30 CA016520 | NCI NIH HHS | United States | P30CA016520 | PubMed | NIH RePORTER |
| U01 AG066100 | NIA NIH HHS | United States | U01AG066100 | PubMed | NIH RePORTER |
| Engineering Research Center for Cell Manufacturing Technologies | National Science Foundation (NSF) | PubMed | PubMed |
References56
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25317870 | Chimeric antigen receptor T cells for sustained remissions in leukemia. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25317870 | PubMed |
| 2 | 35058619 | AI in health and medicine. | Nat Med | 2022 | https://conductscience.org/library/papers/35058619 | PubMed |
| 3 | 41803255 | Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/41803255 | PubMed |
| 4 | 11390513 | Eotaxin (CCL11) induces in vivo angiogenic responses by human CCR3+ endothelial cells. | J Immunol | 2001 | https://conductscience.org/library/papers/11390513 | PubMed |
| 5 | 33328120 | Clinical applications of continual learning machine learning. | Lancet Digit Health | 2020 | https://conductscience.org/library/papers/33328120 | PubMed |
| 6 | 29218881 | Data-driven advice for applying machine learning to bioinformatics problems. | Pac Symp Biocomput | 2018 | https://conductscience.org/library/papers/29218881 | PubMed |
| 7 | 31636098 | Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31636098 | PubMed |
| 8 | 38057668 | Dictionary of immune responses to cytokines at single-cell resolution. | Nature | 2024 | https://conductscience.org/library/papers/38057668 | PubMed |
| 9 | 29226797 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. | N Engl J Med | 2017 | https://conductscience.org/library/papers/29226797 | PubMed |
| 10 | 33596362 | Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33596362 | PubMed |
| 11 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 12 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 13 | 16340423 | Interleukin-8. | Crit Care Med | 2005 | https://conductscience.org/library/papers/16340423 | PubMed |
| 14 | 26738796 | Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/26738796 | PubMed |
| 15 | 23825369 | mRMRe: an R package for parallelized mRMR ensemble feature selection. | Bioinformatics | 2013 | https://conductscience.org/library/papers/23825369 | PubMed |
| 16 | 19358741 | flowCore: a Bioconductor package for high throughput flow cytometry. | BMC Bioinformatics | 2009 | https://conductscience.org/library/papers/19358741 | PubMed |
| 17 | 12563297 | Interleukin-12 and the regulation of innate resistance and adaptive immunity. | Nat Rev Immunol | 2003 | https://conductscience.org/library/papers/12563297 | PubMed |
| 18 | 32298202 | Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32298202 | PubMed |
| 19 | 35110735 | Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. | Nature | 2022 | https://conductscience.org/library/papers/35110735 | PubMed |
| 20 | 27586051 | The parameter sensitivity of random forests. | BMC Bioinformatics | 2016 | https://conductscience.org/library/papers/27586051 | PubMed |
Cited by11
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42966861 | Prognostic scores and biomarkers in hematologic malignancies: current evidence and future perspectives. | Biomark Res | 2026 | https://conductscience.org/library/papers/42966861 | PubMed |
| 42919964 | Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma. | Nat Med | 2026 | https://conductscience.org/library/papers/42919964 | PubMed |
| 42909370 | mRNA-dendritic cell antigen vaccine potentiates CD38 CAR-T Cell therapy for relapsed/refractory acute myeloid leukemia. | Theranostics | 2026 | https://conductscience.org/library/papers/42909370 | PubMed |
| 42819351 | CAR T cell cancer immunotherapy: who does the job? | Front Immunol | 2026 | https://conductscience.org/library/papers/42819351 | PubMed |
| 42713305 | AI and authorship: Norms and uses to preserve human-led science. | PNAS Nexus | 2026 | https://conductscience.org/library/papers/42713305 | PubMed |
| 42681680 | A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42681680 | PubMed |
| 42480604 | Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/42480604 | PubMed |
| 42198346 | Early Immune Signature Features, Including TLR2 and TLR4 Expression, Are Associated with Complete Remission After CD19 CAR-T Cell Therapy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42198346 | PubMed |
| 42122207 | Determinants of Chimeric Antigen Receptor (CAR) T Cell Success: In Vitro and In Vivo Preclinical Assessment. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42122207 | PubMed |
| 42088834 | Remodeling memory T cells with chemotherapy and immune checkpoint inhibitors as host pre-conditioning to empower in vivo CAR-T therapy. | Synth Syst Biotechnol | 2026 | https://conductscience.org/library/papers/42088834 | PubMed |
| 41803255 | Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer. | Nat Biomed Eng | 2026 | https://conductscience.org/library/papers/41803255 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41803255
GET https://conductscience.org/api/papers/v1/41803255/authors?page=2